Sarepta Therapeutics, Inc.
For the period ended Sep 30, 2026. Filed Nov 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report on Form 10-Q.
EXHIBIT INDEX
| Incorporated by Reference toFilings Indicated | ||||||
|---|---|---|---|---|---|---|
| ExhibitNumber | Exhibit Description | Form | FileNo. | Exhibit | FilingDate | ProvidedHerewith |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K12B | 001-14895 | 3.1 | 6/6/13 | |
| 3.2 | Amendment to the Amended and Restated Certificate of Incorporation. | 8-K | 001-14895 | 3.1 | 6/30/15 | |
| 3.3 | Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Sarepta Therapeutics, Inc. | 8-K | 001-14895 | 3.1 | 6/8/20 | |
| 3.4 | Amended and Restated Bylaws. | 8-K | 001-14895 | 3.1 | 9/25/14 | |
| 3.5 | Amendment No. 1 to the Amended and Restated Bylaws. | 8-K | 001-14895 | 3.1 | 1/13/20 | |
| 3.6 | Second Amended and Restated Bylaws. | 8-K | 001-14895 | 3.1 | 12/13/22 | |
| 3.7 | Amendment No. 1 to Second Amended and Restated Bylaws of Sarepta Therapeutics, Inc. | 8-K | 001-14895 | 3.1 | 9/16/24 | |
| 10.1† | Employment Agreement, dated July 24, 2026, by and between Michael Severino, M.D., and Sarepta Therapeutics, Inc. | 8-K | 001-14895 | 10.1 | 7/27/26 | |
| 10.2† | Consulting and Advisory Agreement, dated July 26, 2026, by and between Douglas Ingram and Sarepta Therapeutics, Inc. | 8-K | 001-14895 | 10.2 | 7/27/26 | |
| 10.3^ | Settlement Agreement between REGENXBIO Inc., The Trustees of the University of Pennsylvania, Sarepta Therapeutics, Inc., Sarepta Therapeutics Three, LLC, and Catalent, Inc., entered into as of September 23, 2026. | X | ||||
| 31.1 | Certification of the Company’s Principal Executive Officer, Michael Severino, M.D., pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 31.2 | Certification of the Company’s Principal Financial and Accounting Officer, Ryan H. Wong, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.1* | Certification of the Company’s Principal Executive Officer, Michael Severino, M.D., pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 32.2* | Certification of the Company’s Principal Financial and Accounting Officer, Ryan H. Wong, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | X | ||||
| 101.INS | Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document | X | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | X | ||||
| 104 | Cover page formatted as Inline XBRL and contained in Exhibit 101 | X | ||||
† Indicates management contract or compensatory plan, contract or arrangement.
- The Certifications attached as Exhibits 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filings of Sarepta Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
^ Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) the type of information the registrant treats as private or confidential.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.